Phase I Study of the First-In-Class Agent CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Devimistat (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Cornerstone Pharmaceuticals Inc
- 28 Aug 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 Nov 2022 Planned End Date changed from 1 Jun 2024 to 1 Nov 2024.
- 10 Nov 2022 Planned primary completion date changed from 1 Dec 2023 to 1 Mar 2024.